Skip to content
How It Works
Explore
Resources Ask a Question
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Ask a Question
PubMed This is a summary of 24 peer-reviewed journal articles Updated
Hematology

Treatment Strategies & Guidelines for Hemophilia A

At a Glance

The standard of care for Hemophilia A is prophylaxis to prevent bleeds and protect joint health. Modern treatment options include extended half-life IV factors, subcutaneous emicizumab (Hemlibra) injections, and one-time gene therapy for eligible adults.

Treatment for Hemophilia A has entered a new era. While the goal was once simply to stop a bleed after it started (on-demand therapy), the modern standard of care is prophylaxis—regularly scheduled treatment designed to prevent bleeds before they happen [1][2].

The Shift to Prophylaxis: Protecting Your Joints

The World Federation of Hemophilia (WFH) now strongly recommends primary prophylaxis for children with severe Hemophilia A [3]. This usually begins between ages 1 and 2, or even before the first joint bleed occurs [1].

  • The Goal: The aim is “zero bleeds.” By keeping Factor VIII levels higher, we can prevent the silent, long-term joint damage (arthropathy) that used to be common in hemophilia [4][2].
  • The Outcome: Prophylaxis is proven to provide better joint function and a higher quality of life compared to waiting for a bleed to happen [5].

Modern Treatment Options

You and your care team have several different types of “tools” to keep your Factor VIII levels safe.

1. Extended Half-Life (EHL) Factors

Traditional factor replacement must be infused into a vein (IV) several times a week because it leaves the body quickly. Extended Half-Life (EHL) products stay in the blood longer.

  • How they work: These proteins are modified to bypass the body’s natural “cleaning” process. For example, efanesoctocog alfa stays in the system 3 to 4 times longer than older products [6][7].
  • The Benefit: High, protective levels can often be maintained with just one infusion per week, providing “normal-to-near-normal” protection for most of that week [8][4].
  • At-Home Care: Giving IV infusions at home can sound intimidating, but your Hemophilia Treatment Center (HTC) will provide thorough self-infusion training. For young children, a port-a-cath (a small implanted device under the skin) is often used to make IV access much easier and less stressful.

2. Non-Factor Therapy: Emicizumab (Hemlibra)

Emicizumab is a different kind of medicine called a bispecific antibody. It does not replace Factor VIII; instead, it “mimics” what Factor VIII does by bridging other proteins (Factors IX and X) together to help the blood clot [9][10].

  • Administration: It is given as a subcutaneous injection (under the skin, like an insulin shot) once a week, every two weeks, or once a month [11][12].
  • Special Case: Because it isn’t actually Factor VIII, it works even in patients who have developed inhibitors (antibodies that block traditional factor treatments) [13][14].
  • Safety Warning: Emicizumab severely interferes with standard aPTT coagulation tests (the common lab test for clotting). If you are on emicizumab, standard aPTT tests will falsely show normal clotting times, which could lead emergency room doctors to dangerously withhold life-saving bypassing agents during an active bleed. You must inform ER staff of this and use specialized “chromogenic” lab tests [15].

3. Rebalancing Therapies: Fitusiran

This is a newer approach that doesn’t add clotting factors but instead lowers a protein called antithrombin that naturally slows down clotting. By “rebalancing” the system, it helps the body produce more thrombin to stop bleeds [16][17]. It is given subcutaneously once a month [18].

  • Safety Warning: Because fitusiran intentionally tips the balance toward clotting, it carries a risk of over-correction, potentially leading to unwanted and dangerous blood clots (thrombosis).

The Horizon: Gene Therapy

For adults with severe Hemophilia A, gene therapy (valoctocogene roxaparvovec) is now an approved option [19].

  • How it works: A one-time IV infusion delivers a functional F8 gene to the liver, which then begins producing its own Factor VIII [20].
  • Eligibility: It is currently for adults (18+) without a history of inhibitors and without pre-existing immunity to the viral “delivery truck” (AAV5) used in the treatment [21][22].
  • The Burden of Monitoring: While the infusion is a one-time event, gene therapy requires significant long-term management. There is a high risk of liver inflammation (transaminitis), meaning patients require intense blood testing for liver health and often must take corticosteroids or other immunosuppressants for several months to protect the liver and ensure the therapy works [23][24].

Treatment Checklist

Feature Factor Replacement (EHL) Non-Factor (Emicizumab) Gene Therapy
Delivery Intravenous (IV) Subcutaneous (Under skin) One-time IV
Frequency Weekly or more Weekly to Monthly Single dose
Monitors Factor VIII levels Bleeding frequency Factor VIII levels / Liver enzymes
Target Population All ages All ages Adults (18+)

Common questions in this guide

What is the modern goal of Hemophilia A treatment?
The standard of care has shifted to prophylaxis, which involves regularly scheduled treatments to prevent bleeds before they happen. The ultimate goal is zero bleeds to protect joint health over time.
What are extended half-life (EHL) factors?
Extended half-life factors are modified Factor VIII proteins that stay in your bloodstream much longer than traditional treatments. This allows you to maintain protective factor levels with fewer intravenous infusions, often just once a week.
How does emicizumab (Hemlibra) work differently than factor replacement?
Emicizumab is a bispecific antibody given as a subcutaneous injection under the skin. Instead of replacing Factor VIII, it mimics its function by bringing other clotting proteins together, making it effective even for patients who have developed inhibitors.
What should I tell emergency room staff if I use emicizumab?
You must explicitly inform emergency doctors that you are on emicizumab because it falsely normalizes standard aPTT clotting tests. Specialized chromogenic lab tests are required to accurately measure your clotting function and avoid dangerous treatment errors during a bleed.
What are the long-term monitoring requirements for Hemophilia A gene therapy?
While gene therapy is a one-time infusion, it requires intense long-term blood testing to monitor liver health. Patients often need to take immunosuppressants for months to manage liver inflammation and ensure the therapy remains effective.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.Given our lifestyle, would an EHL factor or a non-factor therapy like emicizumab be a better fit?
  2. 2.Is my child a candidate for 'primary prophylaxis' now, and what is the goal for their joint health?
  3. 3.How do we monitor Factor VIII levels if we switch to emicizumab, and which lab tests should we use?
  4. 4.If we choose gene therapy (for adults), what are the long-term risks regarding liver health and factor levels over time?
  5. 5.How does the 'zero bleeds' goal change our daily activities or sports participation?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (24)
  1. 1

    Long-term impact of primary prophylaxis on joint status in patients with severe hemophilia A.

    Meijón Ortigueira MDM, Álvarez-Román MT, De La Corte Rodríguez H, et al.

    Research and practice in thrombosis and haemostasis 2023; (7(1)):100005 doi:10.1016/j.rpth.2022.100005.

    PMID: 36891521
  2. 2

    International Society on Thrombosis and Haemostasis clinical practice guideline for treatment of congenital hemophilia A and B based on the Grading of Recommendations Assessment, Development, and Evaluation methodology.

    Rezende SM, Neumann I, Angchaisuksiri P, et al.

    Journal of thrombosis and haemostasis : JTH 2024; (22(9)):2629-2652 doi:10.1016/j.jtha.2024.05.026.

    PMID: 39043543
  3. 3

    Aspects of prophylactic treatment of hemophilia.

    Ljung R

    Thrombosis journal 2016; (14(Suppl 1)):30 doi:10.1186/s12959-016-0103-3.

    PMID: 27766056
  4. 4

    Efanesoctocog Alfa Prophylaxis for Patients with Severe Hemophilia A.

    von Drygalski A, Chowdary P, Kulkarni R, et al.

    The New England journal of medicine 2023; (388(4)):310-318 doi:10.1056/NEJMoa2209226.

    PMID: 36720133
  5. 5

    [Effect of FVIII doses on joint structure and function in adolescents with severe hemophilia A: mid-term results of a prospective cohort study].

    Meng L, Zhuang J, Sun X, et al.

    Nan fang yi ke da xue xue bao = Journal of Southern Medical University 2021; (41(4)):536-542 doi:10.12122/j.issn.1673-4254.2021.04.08.

    PMID: 33963712
  6. 6

    Pharmacokinetic evaluation of efanesoctocog alfa: breakthrough factor VIII therapy for hemophilia A.

    Yada K, Nogami K

    Expert opinion on drug metabolism & toxicology 2025; (21(1)):5-14 doi:10.1080/17425255.2024.2409931.

    PMID: 39323385
  7. 7

    Efanesoctocog alfa elicits functional clot formation that is indistinguishable to that of recombinant factor VIII.

    Demers M, Aleman MM, Kistanova E, et al.

    Journal of thrombosis and haemostasis : JTH 2022; (20(7)):1674-1683 doi:10.1111/jth.15741.

    PMID: 35466511
  8. 8

    Perioperative Management With Efanesoctocog Alfa in Patients With Haemophilia A in the Phase 3 XTEND-1 and XTEND-Kids Studies.

    Klamroth R, von Drygalski A, Hermans C, et al.

    Haemophilia : the official journal of the World Federation of Hemophilia 2025; (31(3)):391-400 doi:10.1111/hae.70017.

    PMID: 40099428
  9. 9

    Emicizumab prophylaxis in patients with haemophilia A with and without inhibitors.

    Ebbert PT, Xavier F, Seaman CD, Ragni MV

    Haemophilia : the official journal of the World Federation of Hemophilia 2020; (26(1)):41-46 doi:10.1111/hae.13877.

    PMID: 31746522
  10. 10

    The role of emicizumab, a bispecific factor IXa- and factor X-directed antibody, for the prevention of bleeding episodes in patients with hemophilia A.

    Knight T, Callaghan MU

    Therapeutic advances in hematology 2018; (9(10)):319-334 doi:10.1177/2040620718799997.

    PMID: 30344994
  11. 11

    Prophylactic emicizumab for hemophilia A in the Asia-Pacific region: A randomized study (HAVEN 5).

    Yang R, Wang S, Wang X, et al.

    Research and practice in thrombosis and haemostasis 2022; (6(2)):e12670 doi:10.1002/rth2.12670.

    PMID: 35284778
  12. 12

    Low immunogenicity of emicizumab in persons with haemophilia A.

    Schmitt C, Emrich T, Chebon S, et al.

    Haemophilia : the official journal of the World Federation of Hemophilia 2021; (27(6)):984-992 doi:10.1111/hae.14398.

    PMID: 34480814
  13. 13

    European principles of inhibitor management in patients with haemophilia: implications of new treatment options.

    Hermans C, Giangrande PLF, O'Mahony B, et al.

    Orphanet journal of rare diseases 2020; (15(1)):219 doi:10.1186/s13023-020-01511-8.

    PMID: 32831110
  14. 14

    Disruptive technology and hemophilia care: The multiple impacts of emicizumab.

    Hermans C, Makris M

    Research and practice in thrombosis and haemostasis 2021; (5(4)):e12508 doi:10.1002/rth2.12508.

    PMID: 34027289
  15. 15

    Laboratory issues in gene therapy and emicizumab.

    Bowyer AE, Lowe AE, Tiefenbacher S

    Haemophilia : the official journal of the World Federation of Hemophilia 2021; (27 Suppl 3()):142-147 doi:10.1111/hae.13976.

    PMID: 32469128
  16. 16

    Antithrombin lowering in hemophilia: a closer look at fitusiran.

    Young G, Lenting PJ, Croteau SE, et al.

    Research and practice in thrombosis and haemostasis 2023; (7(4)):100179 doi:10.1016/j.rpth.2023.100179.

    PMID: 37358958
  17. 17

    An investigational RNAi therapeutic targeting antithrombin for the treatment of hemophilia A and B.

    Machin N, Ragni MV

    Journal of blood medicine 2018; (9()):135-140 doi:10.2147/JBM.S159297.

    PMID: 30174468
  18. 18

    Rebalancing Hemostasis: Fitusiran as a First-in-Class RNAi Therapy in Hemophilia A and B.

    Rehman RU, Fatima R, Akilimali A

    Health science reports 2026; (9(1)):e71702 doi:10.1002/hsr2.71702.

    PMID: 41473775
  19. 19

    First conditional marketing authorization approval in the European Union for hemophilia "A" gene therapy.

    VandenDriessche T, Pipe SW, Pierce GF, Kaczmarek R

    Molecular therapy : the journal of the American Society of Gene Therapy 2022; (30(11)):3335-3336 doi:10.1016/j.ymthe.2022.09.020.

    PMID: 36261044
  20. 20

    Persistence of haemostatic response following gene therapy with valoctocogene roxaparvovec in severe haemophilia A.

    Pasi KJ, Laffan M, Rangarajan S, et al.

    Haemophilia : the official journal of the World Federation of Hemophilia 2021; (27(6)):947-956 doi:10.1111/hae.14391.

    PMID: 34378280
  21. 21

    Early Phase Clinical Immunogenicity of Valoctocogene Roxaparvovec, an AAV5-Mediated Gene Therapy for Hemophilia A.

    Long BR, Veron P, Kuranda K, et al.

    Molecular therapy : the journal of the American Society of Gene Therapy 2021; (29(2)):597-610 doi:10.1016/j.ymthe.2020.12.008.

    PMID: 33309883
  22. 22

    Valoctocogene Roxaparvovec Gene Therapy for Hemophilia A.

    Ozelo MC, Mahlangu J, Pasi KJ, et al.

    The New England journal of medicine 2022; (386(11)):1013-1025 doi:10.1056/NEJMoa2113708.

    PMID: 35294811
  23. 23

    Corticosteroid use to mitigate transaminitis-associated decline in FVIII levels following valoctocogene roxaparvovec gene therapy: clinical practice guidance.

    Konkle BA, Peyvandi F, Foster GR, et al.

    Journal of thrombosis and haemostasis : JTH 2025; (23(7)):2086-2094 doi:10.1016/j.jtha.2025.02.042.

    PMID: 40090623
  24. 24

    Liver health in hemophilia in the era of gene therapy.

    Dargaud Y, Levrero M, Bailly F, et al.

    Thrombosis research 2024; (240()):109064 doi:10.1016/j.thromres.2024.109064.

    PMID: 38878740

This page provides educational information about Hemophilia A treatments and guidelines. Always consult your hematologist or Hemophilia Treatment Center before changing your therapy regimen.

Get notified when new evidence is published on Hemophilia A.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.